Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Investing.com - Checkpoint Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Checkpoint Therapeutics announced earnings per share of $-0.120 on revenue of $48K. Analysts polled by Investing.com EPS of $-0.158 on revenue of $17.5K.
Checkpoint Therapeutics 's are down 48.09% and is trading at $0.716 , still down 84.23% from its 52 week high of $4.54 set on Tuesday, November 9, 2021.
Checkpoint Therapeutics follows other major Healthcare sector earnings this month
Checkpoint Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar